𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Dissolution behavior and bioavailability of phenytoin from a ground mixture with microcrystalline cellulose

✍ Scribed by Keiji Yamamoto; Masahiro Nakano; Takaichi Arita; Yoshikazu Takayama; Yoshinobu Nakai


Book ID
102914351
Publisher
John Wiley and Sons
Year
1976
Tongue
English
Weight
557 KB
Volume
65
Category
Article
ISSN
0022-3549

No coin nor oath required. For personal study only.

✦ Synopsis


The ground mixture of phenytoin and microcrystalline cellulose was prepared by grinding in a vibrational ball mill. The X-ray diffraction patterns indicated the amorphous nature of the ground mixture. Comparative studies were made concerning the in vitro dissolution and in vivo absorption of fine phenytoin powder, phenytoin sodium powder, and the ground mixture. The ground mixture showed a greater dissolution rate than the fine powder and attained supersaturation in the pharmacopeial disintegration media at pH 1.2 and 7.4. In vivo absorption studies of each preparation were carried out in five subjects, using a crossover design, by measuring the urinary excretion rate of a main metabolite, 5-(p-hydroxyphenyl)-5-phenylhydantoin. The blood levels of phenytoin and the corresponding urinary excretion patterns of the metabolite were determined in two subjects. The ground mixtures significantly improved the bioavailability of phenytoin. The drug was completely and rapidly absorbed after oral administration of the ground mixture. The vibrational ball milling technique for a poorly water-soluble drug with microcrystalline cellulose provides a promising way of improving the in vivo drug absorption.


📜 SIMILAR VOLUMES


Bioavailability of phenylbutazone from a
✍ V. A. John; S. Goldsborough; P. J. Morrison; Dr. H. J. Rogers; R. G. Spector; I. 📂 Article 📅 1982 🏛 John Wiley and Sons 🌐 English ⚖ 341 KB 👁 1 views

## Abstract The bioavailability of an improved formulation of enteric‐coated phenylbutazone with faster dissolution, more consistent __in vitro__ rate of drug release and improved stability was compared in 8 normal subjects at doses of 100 and 200 mg with commercially available Butacote®. Phenylbut